Katarzyna Gliniewicz

Mrs. Katarzyna Gliniewicz

International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2021 in British Journal of Cancer
Verified
Journal Article
Closed access
PDF file
DWDominika Wokołorczyk
Dominika Wokołorczyk
WKWojciech Kluźniak
Wojciech Kluźniak
KSKlaudia Stempa
Klaudia Stempa
BRBogna Rusak
Bogna Rusak
THTomasz Huzarski
Tomasz Huzarski
CCCezary Cybulski
Cezary Cybulski

1 September 2020 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
DWDominika Wokołorczyk
Dominika Wokołorczyk
WKWojciech Kluźniak
Wojciech Kluźniak
THTomasz Huzarski
Tomasz Huzarski
JGJacek Gronwald
Jacek Gronwald
ASAgata Szymiczek
Agata Szymiczek
TCThe Polish Hereditary Prostate Cancer Consortium
The Polish Hereditary Prostate Cancer Consortium

13 October 2019 in Cancers
Verified
Journal Article
Open access
PDF file
WKWojciech Kluźniak
Wojciech Kluźniak
DWDominika Wokołorczyk
Dominika Wokołorczyk
BRBogna Rusak
Bogna Rusak
THTomasz Huzarski
Tomasz Huzarski
AKAniruddh Kashyap
Aniruddh Kashyap
CCCezary Cybulski
Cezary Cybulski
Bloom Syndrome is a rare recessive disease which includes a susceptibility to various cancers. It is caused by homozygous mutations of the BLM gene. To investigate whether heterozygous carriers of a BLM mutation are predisposed to breast cancer, we sequenced BLM in 617 patients from Polish families with a strong family history of breast cancer. We detected a founder mutation (c.1642C>T, p.Gln548Ter) in 3 of the 617 breast cancer patients (0.49%) who were sequenced. Then, we genotyped 14,804 unselected breast cancer cases and 4698 cancer-free women for the founder mutation. It was identified in 82 of 14,804 (0.55%) unselected cases and in 26 of 4698 (0.55%) controls (OR = 1.0; 95%CI 0.6–1.6). Clinical characteristics of breast cancers in the BLM mutation carriers and non-carriers were similar. Loss of the wild-type BLM allele was not detected in cancers from the BLM mutation carriers. No cancer type was more common in the relatives of mutation carriers compared to relatives of non-carriers. The BLM founder mutation p.Gln548Ter, which in a homozygous state is a cause of Bloom syndrome, does not appear to predispose to breast cancer in a heterozygous state. The finding casts doubt on the designation of BLM as an autosomal dominant breast cancer susceptibility gene.

11 February 2025 in Cancers
Verified
Journal Article
Open access
PDF file
SFSylwia Feszak
Sylwia Feszak
Igor Jarosław FeszakIgor Jarosław Feszak
Igor Jarosław Feszak
WKWojciech Kluźniak
Wojciech Kluźniak
DWDominika Wokołorczyk
Dominika Wokołorczyk
KMKlaudia Mróz
Klaudia Mróz
CCCezary Cybulski
Cezary Cybulski
Background/Objectives: Ductal carcinoma in situ (DCIS) is the most common non-invasive form of breast cancer. It is not clear to what extent DCIS is a part of the hereditary breast/ovarian cancer syndrome caused by BRCA1/2 mutations. Therefore, we investigated the association of BRCA1/2 mutations in patients with DCIS and assessed their impact on survival. Methods: We studied 564 Polish women with DCIS for six alleles in BRCA1 (c.181T>G, c.5266dupC, c.4035delA, c.3700_3704del5, c.68_69del and c.5251C>T) and four in BRCA2 (c.658_659del, c.3847_3848del, c.5946del and c.7913_7917del). To investigate the association of BRCA1/2 founder mutations with DCIS risk, we tested 4702 controls as a reference. To analyze survival, mutation carriers were followed for an average of 110 months. Results: A BRCA1 mutation was present in seven (1.24%) cases and in twenty-two (0.47%) controls (OR = 3.27, 95%CI 1.36 to 7.87, p = 0.01). A BRCA2 mutation was present in eight (1.42%) cases versus six (0.13%) controls (OR = 11.3, 95%CI 3.9 to 32.6, p < 0.0001). Three of the fifteen cases with BRCA1/2 mutations developed invasive ipsilateral or contralateral breast cancer, on average 6 years from the diagnosis of DCIS. There were no deaths reported among the 15 mutation carriers with DCIS. Conclusions: DCIS is a part of the hereditary breast/ovarian cancer syndrome caused by BRCA1/2 mutations. Women with DCIS should receive genetic counseling and testing for BRCA1/2 mutations. BRCA1/2 mutations may predispose women to a better DCIS prognosis, but further studies are needed.

30 October 2021 in Cancers
Verified
Journal Article
Open access
PDF file
KMKlaudia Mróz
Klaudia Mróz
DWDominika Wokołorczyk
Dominika Wokołorczyk
WKWojciech Kluźniak
Wojciech Kluźniak
EREmilia Rogoża-Janiszewska
Emilia Rogoża-Janiszewska
KRKarolina Rowińska
Karolina Rowińska
OCon behalf of the Polish Hereditary Prostate Cancer Consortium
on behalf of the Polish Hereditary Prostate Cancer Consortium
The current cancer testing gene panels tend to be comprehensive rather than site-specific. BARD1 is one of the genes commonly included in the multi-cancer testing panels. Mutations in BARD1 confer an increase in the risk for breast cancer, but it is not studied whether or not they predispose to prostate cancer. To establish if BARD1 mutations also predispose to prostate cancer, we screened BARD1 in 390 Polish patients with hereditary prostate cancer. No truncating mutations were identified by sequencing. We also genotyped 5715 men with unselected prostate cancer, and 10,252 controls for three recurrent BARD1 variants, including p.Q564X, p.R658C and p.R659=. Neither variant conferred elevated risk of prostate cancer (ORs between 0.84 and 1.15, p-values between 0.57 and 0.93) nor did they influence prostate cancer characteristics or survival. We conclude that men with a BARD1 mutation are not at elevated prostate cancer risk. It is not justified to inform men about increased prostate cancer risk in case of identification of a BARD1 mutation. However, a female relative of a man with a BARD1 mutation may benefit from this information and be tested for the mutation, because BARD1 is a breast cancer susceptibility gene.

24 June 2023 in Genes
Verified
Journal Article
Open access
PDF file
KGKatarzyna Gliniewicz
Katarzyna Gliniewicz
WKWojciech Kluźniak
Wojciech Kluźniak
DWDominika Wokołorczyk
Dominika Wokołorczyk
THTomasz Huzarski
Tomasz Huzarski
KMKlaudia Mróz
Klaudia Mróz
CCCezary Cybulski
Cezary Cybulski
The APOBEC3B gene belongs to a cluster of DNA-editing enzymes on chromosome 22 and encodes an activation-induced cytidine deaminase. A large deletion of APOBEC3B was associated with increased breast cancer risk, but the evidence is inconclusive. To investigate whether or not APOBEC3B is a breast cancer susceptibility gene, we sequenced this gene in 617 Polish patients with hereditary breast cancer. We detected a single recurrent truncating mutation (c.783delG, p.Val262Phefs) in four of the 617 (0.65%) hereditary cases by sequencing. We then genotyped an additional 12,484 women with unselected breast cancer and 3740 cancer-free women for the c.783delG mutation. The APOBEC3B c.783delG allele was detected in 60 (0.48%) unselected cases and 19 (0.51%) controls (OR = 0.95, 95% CI 0.56–1.59, p = 0.94). The allele was present in 8 of 1968 (0.41%) familial breast cancer patients from unselected cases (OR = 0.80, 95% CI 0.35–1.83, p = 0.74). Clinical characteristics of breast tumors in carriers of the APOBEC3B mutation and non-carriers were similar. No cancer type was more frequent in the relatives of mutation carriers than in those of non-carriers. We conclude the APOBEC3B deleterious mutation p.Val262Phefs does not confer breast cancer risk. These data do not support the hypothesis that APOBEC3B is a breast cancer susceptibility gene.